A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of selected advanced or metastatic
solid tumors.

- Presence of measurable disease per RECIST v1.1.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

- Laboratory and medical history parameters not within the Protocol-defined range.

- Receipt of anticancer medications or investigational drugs within the Protocol-defined
intervals before the first administration of study drug.

- Previous radiotherapy within 2 weeks of starting study therapy.

- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

- Has not recovered to ≤ Grade 1 from toxic effects of previous therapy and/or
complications from previous surgical intervention before starting study therapy.

- Receipt of a live vaccine within 30 days of planned start of study therapy.

- Active infection requiring systemic therapy.

- Subjects who have any active or inactive autoimmune disease or syndrome.

- Women who are pregnant or breastfeeding.